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Abstract
Coronary Artery Disease (CAD) is responsible for 1 death every minute in the US. Angioplasty with the
implantation of stents is a common treatment method for CAD. Although there is a variety of stents
currently on the market, there is still a need to develop new types for different pathologic conditions.
Preliminary assessment of the physiological response to new stents is needed as they are being
developed. The FDA approval process implemented today is a long, tedious path with a range of testing
methods that include static in vitro testing and high-cost animal testing. Tissue engineered blood
vessels have been used to create “blood vessel mimics” (BVM) as an intermediate step to improve the
evaluation process. A previous Cal Poly tissue engineering student, Sarah Ur, developed a BVM
protocol as part of her senior project. The aim of my senior project is to investigate the reproducibility
of the existing BVM protocol for creating confluent cell linings on the interior lining of a polymer
scaffold.
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Section 1. Introduction
Background
Coronary Artery Disease (CAD), also known as Coronary Heart Disease (CHD), is the leading cause of
death in the United States and was responsible for 1 of every 6 deaths in 20081. CAD leads to
decreased blood supply to the heart due to the narrowing and hardening of the small blood vessels 2.
CAD results from cholesterol and other materials that gradually accumulate and form plaque on the
endothelial lining of the blood vessels. The hardening of accumulated plaque on the blood vessel walls
is known as atherosclerosis2 as illustrated in Figure 1, which causes decreased blood flow to the heart3.
If the plaque breaks from the blood vessel wall, it can form a clot that can lead to a myocardial infarction3. The

supply of blood or oxygen to the heart is less than the demand 2. Pain in the chest is referred to as
Angina and is one of the most common symptoms2. Other symptons with decreased blood suppy
include: fatigue, and shortness of breath2; abnormal feelings in the neck, arm, stomach, upper back can
also be related to coronary artery disease2. However, some patients with decreased blood flow to their
heart can continue with their daily routine without any symptoms . Although coronary-artery bypass
grafting has been historically used as the treatment of choice, angioplasty is a preferred minimally
invasive method for treating coronary artery disease4.
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Figure 1: Plaque buildup in the blood vessel decreases the needed blood and oxygen supply to heart 2
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Current Treatments
Angioplasty is a common treatment method for coronary artery disease in which the procedure
expands the cavity of the clogged blood vessel to restore the blood supply to the heart. Issues with restenosis occurred with angioplasty alone, so a stent is commonly used in conjunction5. As depicted in
figure 2, a catheter is guided to the affected artery; a balloon at the tip of the catheter is blown up to
squeeze the buildup against the vessel wall to restore the original size of the vessel lumen3. Although
angioplasty alone was a revolutionary step in interventional cardiology, the procedure alone may result
in occlusion and re-stenosis, therefore to prevent re-stenosis a mechanical support was created. A
stent is a wire mesh tube guided to the block area using a balloon catheter. The stent is employed to
the keep the diseased vessel from closing up again4-5.

Figure 2: Atherosclerotic blood vessel undergoing the angioplasty process6

Current Stent Methods
The first stent was a bare metal stent known as the “Wall Stent” that was implanted in 1986
and prevented acute vessel closure and late constrictive recoil 7. Figure 3 illustrates a coronary artery
stent. As a result, the need for emergency coronary artery bypass surgery (CABG) was reduced.
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However, up to 18% of cases resulted in subacute thrombotic coronary artery occlusion, therefore
anticoagulation regimens were implemented with the bare metal stent, devices which were later
discovered to cause increased bleeding7. Stents were not trusted until two studies, the BENESTENT and
STRESS study, were conducted to ensure the safety of the prosthetic implants7. Since then the use of
stents has allowed tremendous growth in the field of interventional cardiology8. Drug eluting stents
(DES) were created to address neointimal hyperplasia issues. As illustrated in Figure 4, the benefit of
the DES is that the drugs are delivered directly to the affected area maximizing the drug effect, saving a
lot of time and money for those who have DES implant8.

Figure 3: Illustrates a stent in the coronary artery and the location on the heart 2
Although some companies have diverged from the original stent to focus on the rapidly growing field
of covered and biodegradable stents, there is still a steady emphasis on non-pharmacological coatings
and new bare stent materials9. Even though there are a number of configurations, materials, and
coatings, there is still a need to develop more. The pathway for approval of stents in US markets is
time-consuming, costly, and is often performed more in vivo animal studies than needed. There is a
need to create an initial physiological assessment of stent devices that can effectively address the
existing issues with the current medical device approval process.
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Figure 4: A schematic of a drug eluting stent with controlled drug release10

Current Testing Methods
Current testing methods must complete a tedious process of bench top testing, in vitro testing, and in
vivo testing before moving into clinical trials (Figure 5). The current pre-clinical testing requirements of
intravascular devices that are recommended to receive FDA approval are: mechanical testing,
biocompatibility testing, and in vivo testing. These tests are all described in the FDA guidance titled
Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated
Delivery Systems11. The guide is FDA’s preferred method even though there is no foolproof stent
testing; the guidance outlines the different non-clinical engineering tests that are intended to prove
the safety and effectiveness of the stents and associated delivery systems. The methods and results
from these tests are needed to apply for investigational device exemption (IDE), which is a
requirement to move into clinical trials. The document also describes recommended labeling for stents
and their associated delivery systems12. The FDA testing system is a well established procedure.
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The dilemma with the testing system is the gap between the in vitro testing and in vivo testing.
A device may pass the simple mechanical tests and biocompatibility tests, but fails entirely when the
stent is employed into a native vessel 11. There are many testing methods that exist, such as 2D static,
ﬂow-based endothelial cell culture, and computational modeling. Yet these methods do not account
for physiological factors such as shear stress and flow13. The path to perform animal testing costs a lot
of time and money. If the device completely fails in the in vivo testing, the device must be reevaluated
and has to undergo the testing process from the beginning. This means the sponsor has to cover the
same costs. Therefore there is a great need for an improved testing method that can act as an
intermediate step between the in vitro bench testing and the in vivo animal testing. Tissue engineered
blood vessels have been grown for implantation; however, there is an emerging field using tissue
engineered blood vessels (TEBV) as a preclinical test environment.

Figure 5: The current testing method to get a device put out on the market 11

Tissue Engineered Blood Vessels
Historically, tissue engineered blood vessels (TEBV) were intended for implantation in affected blood
vessels of those suffering from CAD, however tissue engineered blood vessels for preclinical models
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emerged in 199814. The benefits of TEBV as a preclinical model hold promise to be more physiologically
relevant than computer modeling and can be implemented as the intermediate step between the
initial in vitro testing and in vivo pre clinical testing testing14. The systems are composed of different in
vitro bioreactor and cultivation systems involving various materials for scaffolds, cell types, and
configurations so it can model various conditions and anatomies14. To create a better cell lining and
increase cell adhesion, the scaffolds are conditioned with conditioning prior to seeding13. Since the
TEBV produces a controlled, reproducible model, analysis of the cell interaction and the implant can be
performed. A TEBV can be more useful than a 2D model because the use of TEBVs as preclinical models
can yield better physiological responses because the system is exposed to different flow conditions and
human cells that compose the different layers of the actual vessel. The TEBV closely mimics the
mechanical and chemical properties of the native environment15. The biochemical properties would
include pH, humidity, temperature, pO2 and pC02, while the mechanical properties encompassed are
mass transfer, shear stress, flow, and volume16. The properties modeled from the TEBVs reduce the
need for in vivo testing.
Creating a TEBV will reduce testing costs because it can reduce the number of times a device
needs to go through in vivo testing, and can also eliminate in vivo in some cases13. The tissue
engineered blood vessel can eliminate stents that are not ready to continue on to animal testing and
save companies extraneous costs. During her PhD work at University of Arizona, Dr. Cardinal illustrated
that it was feasible to employ a stent into the TEBV without destroying the BVM system 13. Dr.
Cardinal’s tissue engineering research group focuses on blood vessel mimics with the end goal of
creating a reproducible mimic that stents can be employed in for testing purposes. Although the
system configuration has changed, the established pressure sodding method is implemented with the
new system. A previous student in Cal Poly’s tissue engineering research lab, Sarah Ur, established a
10

BVM protocol with Human Umbilical Vein Endothelial Cells (HUVECs) only. However, the cell lining was
under confluent and as a result a dual sod with both HUVECs and Human Umbilical Artery Smooth
Muscle Cells (HUASMCs) was created. It was shown in literature that the seeding of HUASMCs
increased HUVECs adhesion. The assessment of the Dual Sod protocol confirmed the increased HUVEC
adhesion. The Dual Sod protocol became the established method to create a reproducible and
consistent cell lining of a polymer scaffold in the lab’s new BVM system.

Critical Components of the Cal Poly Tissue Engineered BVM
Three critical components of the system are the scaffold, the smooth muscle cells, and endothelial
cells. The ideal tissue engineering scaffold could elicit physiological responses and act as a mechanical
support much like the extracellular matrix of the native vessel17.

Scaffold Material
The scaffolds are electrospun from other team members in the lab; it is composed of Poly Lactide-coGlycolide Acid (PLGA). PLGA is a widely used material in the medical field because of its
biodegradability, biocompatibility, and mechanical properties. The Food and Drug administration has
already approved the biodegradable polymer17. Electrospinning is the preferred method for composing
scaffolds because of its inexpensive nature, its consistency amongst the scaffolds, and its
reproducibility18.

Cell Types
Human Umbilical Vein Smooth Muscle Cells (HUASMC)
Since smooth muscle cells are vital to the vasculature’s performance and composition, HUVSMCs are
used to mimic the tunica media of the vessel11. HUASMCs are a good source of smooth muscle cells to
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use because they are commercially available for a low cost. The smooth muscle cells will create the
layer between the scaffold and the endothelial lining5.
Human Umbilical Vein Endothelial Cells (HUVECs)
Although Human Coronary Artery Endothelial Cells are more physiologically relevant to the blood
vessels where CAD occurs, HUVECs are available at a lower cost and are also are derived from a large
vessel5. The cells construct the lumen or the innermost lining of the blood vessel mimic.

Purpose
Originally it was established that the aim of my senior project was to implement the dual sod protocol
of HUVECs and HUASMCs to create an in vitro BVM setup; the two cell types were sodded onto PLGA
scaffolds to observe similar confluent cell linings among each of the vessels. The BVM was setup using
the established protocol discussed in the Tissue Engineered Blood Vessels section. After performing a
few setups, challenges such as leaking kept me from obtaining enough data to analyze a reproducible
consistent cell lining. Therefore, the purpose of my senior project changed from observing the
reproducible cell lining into investigating the feasibility of reproducing a confluent cell lining on the
lumen of a scaffold with the existing BVM protocol.
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Section 2. Methods
BVM cultivation
The aim of the project was to investigate the reproducibility of the existing BVM protocol. The methods
of cell culture, sodding protocols, BVM cultivation, specific experiment details, and setup analysis will
be discussed in this section.

Cell Culture
Aseptic cell culture technique in a laminar flow hood was performed under standard condition (37˚C,
5% CO2) using human umbilical vein endothelial cells (HUVECs) and human umbilical vein smooth
muscle cells (HUVSMCs) in their specific media (Lonza EGM-2, Catalog No cc3162 for HUVEC, Lonza
SmGM-2, Catalog No. cc3182 for HUVSMC). Both types of cells were trypsinized and passed if the
confluence of the cells were equal to or above 75%. In order to dilute the tryspin activity and to
promote the growth and proliferation in the new flask, the cells were deactivated with at least double
the amount of cell media to trypsin.

BVM System
The system used for BVM cultivation is composed of a bioreactor connected by tubing to a reservoir of
media and mounted onto a peristaltic pump that generates the flow throughout the closed system. A
CAD drawing of the entire system is shown in Figure 6. There is one stopcock at the proximal end and
two stopcocks at the distal end; the two ports on the distal end are in line with each other and
converge to create a Y connection formation to prevent leaking before the bioreactor chamber is
connected to the tubing to create the closed system. The two distal ports serve for different functions;
13

one blocks flow through the lumen to create transmural flow while the other one acts as a drain.
Pressure sodding of the cells is performed through the release port connected to the tubing
immediately before the proximal end of the bioreactor. The insertion of the scaffold into the
bioreactor is performed before the entire system is assembled; therefore the ports are positioned so
no media can leak out of the bioreactor. Before attaching the scaffolds in the proper fittings, the
bioreactor is filled with roughly 200mL of bioreactor media (56mL FBS, 500mL M199, 5mL
Penicillin/Streptomycin, 5mL L-glutamine) so the fittings in the bioreactor are completely submerged
as seen in Figure 7.

Figure 6: A schematic of the current BVM system11
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Figure 7: 3 cm long PLGA scaffold placement during a BVM setup.

The electrospinning team of Dr. Cardinal’s Tissue Engineering lab provided 12 cm long mandrels of
PLGA, 3 or 4 mm in diameter. The PLGA was cut off the mandrels to create 3 cm long scaffolds and
sutured with silk sutures to luer lock fittings. In order to sterilize the material, the scaffolds were
submerged completely in 70% EtOH for 30 minutes. Immediately following sterilization, the scaffolds
were placed in a trough of DCF-PBS. A 10mL syringe was used to flush the scaffold luminally first and
then transmurally with 3 mL of the DCF-PBS each time. The scaffold was then transferred to a trough
filled with conditioning media and the same flushing procedure was performed again with the
conditioning media. Sterile technique was implemented to transfer the scaffold from the trough to the
bioreactor that was filled with bioreactor media. The scaffold was locked into place by luer lock fittings.
The Tupperware top was snapped on, and a reservoir (50mL conical) filled with conditioning media was
connected to the bioreactor by tubing. The BVM system was assembled inside the hood using aseptic
technique so exposure to contamination was prevented before the system was transferred from the
hood to the humidified incubator. The tubing was mounted onto the pump. The pump was turned on
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and set to 150 RPM as shown in Figure 8. There was luminal flow for 10 minutes or until there were no
more bubbles circulating, and then the lumen was blocked off and transmural flow was performed for
the length of time called for by the specific protocol.

Figure 8: Four day dual setup during the conditioning phase of the experiment

Single Sod Protocol
Conditioning and sodding occurred on the same day for a single sod setup. Conditioning was
performed for 10 minutes. During the 10 minutes of conditioning, 3T3s or HUVECs was trypsinized
when the cells were 80% confluent. 3T3s are mouse fibroblast cells that are used for the initial learning
of cell culture and BVM setup because of costs and low maintenance. The cells were then placed in a
centrifuge and spun down on level 4 for 4 minutes for HUVECS or level 5 for 5 minutes if they were
3T3s. The media was aspirated so that only the pellet of cells was left, the cells were then resuspended
with 3mL of media per scaffold. The cell solution was pressure sodded with the syringe through the
release port on the proximal end and then chased with 3mL of the specific cell media. The system was
mounted onto the 8 roller pump and transmural flow was turned on for 1 hour at 7 rpm. The lumen
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was then unblocked and continued at 7 RPM for 1 hour. The flow was gradually increased to 15 RPM
and left overnight, the next day the system was taken down.

Dual Sod Protocol
HUASMCs in T225 flasks were trypsinized when the cells are 80% confluent and transferred to a 50mL
conical reservoir to be centrifuged into a pellet. Cells were expanded until there was 1 T225 flask of
both HUVEC and HUVSMC for each scaffold used. Both HUASMCs and HUVECs were spun at level 4 for
4 minutes. Depending on the number flasks, cells may have to be spun down twice; if so, media was
aspirated out of the conical until the media and cells from the two conicals would fit into one conical.
The cells are then centrifuged again at level 4 for 4 minutes. The media was completely aspirated so
only the pellet of cells was left. The cells were resuspended within the specific cell media; 3mL of
media per vessel was used for the resuspension so that the cell concentration was approximately 3.3
million cells per milliliter. The cell suspension was transferred to a 50mL trough. Another trough was
filled with the specific cell media. A 10mL syringe was used to pressure sod 3mL of the cell solution
transmurally onto the scaffold through the release port located on the proximal end, and then 3mL of
cell media chaser was immediately injected to ensure the cells reach the scaffold. The luminal surface
was the area of interest and the optimal cell density expected is 1.5x106 cells/cm2. The system was
transferred back to the humidified incubator and transmural flow was performed for 10 minutes
immediately following sodding. The pump was turned off to allow the cells to rest for 1-3 hours. The
same process was then conducted with the HUVECs after the resting period for the HUASMCs was
over. After the HUVECs were pressure sodded, had undergone 10 minutes of transmural flow, and
rested for 1-3 hours, the lumen ports were reopened and luminal flow was turned on at 15 RPM. The
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RPM was increased by 10-15 RPM every 1-2 hours until the RPM reached 55 RPM and the pump was
left on at 55 RPM overnight. The next day the RPM was gradually increased until the RPM reached 90
RPM. The incubator environment was set to mimic physiologic conditions so the temperature is 37˚C
and the percent carbon dioxide was 5% CO2. Appendix A has the complete protocol for Dual Sodding
HUASMCs and HUVECs onto PLGA scaffolds.

Setup 1.
The first experiment of the senior project was a single sod with 3T3s onto a 3.5 cm length ePTFE
scaffold following the single Sod Blood Vessel Mimic Protocol using 1 T225 flask of 3T3 cells. The
experiment was performed under the supervision of Dr. Cardinal since the student was inexperienced
with the protocol. The experiment was performed sterilely in order to become familiar with the
technique. For educational purposes, the experiment was performed sterilely, despite being less than
24 hours in duration. However, sterile technique was broken because of the learning process. Before
the cells were spun down, the trypsin was deactivated with bioreactor media. After the sodding was
completed, the BVM system was placed in the incubator; the system was clamped onto the 8 roller
pump for transmural flow at 7 RPM. The lumen was unclamped and luminal flow was maintained at 7
RPM for 1 hour. Luminal flow was increased to 11 RPM for one hour, and then increased to 15 RPM to
leave overnight. The setup was taken down 25 hours later. Fluorescence analysis was performed using
the bisbenzimide (BBI) stain.
Setup 2
The single Sod Blood Vessel Mimic was executed again except with HUVECs for the first time. The setup
was designed to only have one BVM and be in the incubator for 24 hours. A T225 flask of HUVECs were
used to seed onto a single 3.5 cm length ePTFE scaffold. The HUVEC media was treated with the same
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technique as the 3T3 media, so whole bottle of HUVEC media was placed in the water bath rather than
only warming up the needed amount. Prior to spinning down the cells, the trypsin was deactived with
1:1 ratio of bioreactor media. Transmural flow of 7 RPM was started immediately after sodding for an
hour. The lumen was unclamped and luminal flow was carried out for an hour. After the hour, the
luminal flow was increased to 10 RPM and left overnight. The setup was taken down approximately 24
hours later and the scaffold was placed in Histochoice. Image Analysis was not conducted.
Setup 3
A Single Sod BVM setup similar to setup 1 was performed again using a 3.5 cm long ePTFE scaffold.
Conditioning occurred during the preparation of 1 T225 flask of 3T3 cells. Priming of the scaffold with
the conditioning media did not occur initially because the bioreactor chamber was not a completely
closed system. When the system was thought to be a closed system, the conditioning media still did
not flow throughout. The system remained in the incubator while the cells were being prepared.
Bioreactor media was used to deactivate with a 1:1 ratio. Cell seeding was conducted following the
single sod protocol and the BVM system was returned to the incubator. When the setup was mounted
on the pump, leaking occurred near the reservoir outlets. Parafilm was used for the first time to stop
system’s leaking. The system was taken down and image analysis was not performed.
Setup 4
The setup was the first time performing a dual sod setup, using 3 cm long and 4 mm in diameter PLGA
as the scaffold material, and having multiple BVM systems. Sarah Ur assisted in executing the setup to
help transfer the knowledge and skills of the dual sod technique. The design of the experiment
included two one-day setups and two three-day setups for qualitative analysis between the cell
coverage between the two time points. Since it was four BVM system setup, four T225 flasks for each
cell time were cultured so that there would be one T225 flask of HUVECs and HUASMCs for each
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scaffold. Four 3.5 cm long and 4 mm in diameter PLGA scaffold were cut off the mandrels. One of the
scaffolds was too short, so an extra fitting was needed to fit the scaffold into the fixed fittings on the
chamber walls. Transmural flow at 7 RPM was performed after both sodding procedures for an hour.
The lumen was unclamped and luminal flow was carried out at 15 RPM and left overnight. The leaking
continued so the one-day setup was taken down. The next morning the RPM was gradually increased
until 90 RPM was reached. The RPM was increased to 30 RPM at 11 AM in the morning. 45 RPM was
reached at 2 PM. The speed was increased to 60 RPM at 3 PM, and then increased 75 RPM at 5:45 PM.
The final RPM was reached at 7 PM. Within 24 hours, one of the three-day setup’s tubing tore in the
pump and was immediately taken down. That same day, the one-day setups were taken down and the
three-day setup was taken down two days later. Image analysis was executed using a fluorescence
microscope and the BBI stain.
Setup 5
Setup 5 was performed as a dual sod setup with both HUVECs and HUASMCs. The setup day was
delayed for two days because the building where the tissue engineering was locked over the weekend.
Similarly to setup 4, setup 5 was designed to be a four BVM system setup. The PLGA was left on the
mandrel for five days. Four 3 cm long by 3 mm in diameter scaffolds were cut from the mandrels. Prior
to conditioning day, cell cultured was performed so that there were four T225 flasks of each cell type.
The standard dual BVM protocol was followed. On conditioning day, the scaffolds were left in the
ethanol for 20 minutes longer than the protocol called for. During scaffold placement, one of the
scaffolds became kinked and remained kinked once locked into the fittings. Bubbles started to form
around the kinked scaffold during the conditioning phase of the protocol, so the BVM system was
taken down. The setup was left with two three-day BVMs and one one-day BVM. The scaffolds were
left conditioning overnight. The trypsin was deactivated with bioreactor media during cell preparation.
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After the sodding, transmural flow, and resting of both cell types was completed, luminal flow was
started 15 RPM. 30 RPM was begun at 2 PM. 45 RPM was reached at 3:30 PM. The speed as increased
to 60 RPM at 4:45 PM. The final increases occurred at 6 PM and 7: 20 PM, so the final speed was 90
RPM. The BBI stain was performed following the standard protocol. SEM analysis was carried out for
the first time.
Setup 6
The four BVM setup was intended to be a three-day setup using 3 cm long and 3 mm in diameter PLGA
scaffolds. The setup was originally scheduled for the end of June, but was not conducted until the
beginning of August due to a few reasons. Since the sterilization process occurred at the vet clinic, the
reduced summer hours made completion difficult. Once the vet clinic received components for
sterilization, there was a malfunction with the sterilization process. The setup was delayed two weeks
further due the sterilization malfunction. Once the sterilization process was completed, the tissue
engineering lab had a malfunction with the dewar, so all the tissue engineering lab’s cells were lost.
The mandrels of PLGA were spun a whole month before the setup occurred. Since time was an issue,
the setup duration was intended to be two days instead of three days. The HUASMCs were expanded
at a very slow rate. The setup date could not be delayed so it was decided to decrease the number of
systems for the setup due to the small population of HUASMCs. Three BVM systems were used in the
setup using three T225 flasks of HUVECS and four T225 flasks of HUASMCs. After observing a Sarah
Ur’s setup in the spring, it was decided to deactivate with HUVEC and HUASMC media instead of
bioreactor media; everything else on the dual sod protocol was followed. During the conditioning day,
the CO2 tank was replaced. The conditioning and sodding procedure went according to the protocol.
After the cells undergone the rest and transmural flow duration, the RPM was increased by 15 RPM
every two hours for the luminal flow. The speed was left at 55 RPM over night. The next day, two of
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the bioreactor’s tubing came off of the fittings and caused the system to be exposed to the
surrounding environment. One of the bioreactors had to be taken down immediately due to a foul
smell and yellow coloring. The other system was attempted to be salvaged. However, within the hour
the salvaged system turned yellow. The setup ended up with only one system. The RPM continued to
be increased every two hours until 90 RPM was reached. The system was taken down the next day.
Florescence and SEM imaging was performed six weeks later.

Setup 7
The cells were expanded from P1 to P4 from the lab manager, so each member would receive a T75 of
both HUVECs and HUASMCs. The SMCs grew at such a slow rate that the setup could not be performed
on the scheduled date. The cells had to be frozen down. The lab manager froze down the HUVECs for
training purpose. The student performing the setup froze down the HUASMCs; a total of 24 vials of
cells (12 of each cell type) were frozen down. Three frozen vials of cells were then thawed into one
T225 flask one week later, so that were would be four T225 flasks of each cell type. Although both cell
types were 100% confluent in each flask prior to freezing down, the HUVECs were 15% confluent and
the HUASMCs were 60% confluent when thawed. Since the HUVECs were growing at such a slow rate,
three more frozen vials of HUVECs were thawed into a T225 a day before the conditioning procedure.
On conditioning day, the bioreactor systems were transferred to the incubator, and puddles of
bioreactor media were left in the hood space. Two of the four BVMs were leaking; Parafilm was
implemented to prevent any more leaking. The four BVMs were left overnight conditioning. The next
morning, three of the four bioreactors had to be taken down; Leaking in two of the bioreactors
continued, and tubing broke in the third BVM system. Only one BVM system was left for sodding; one
T225 flask of HUASMC at 100% confluency and two T225 flasks of HUVECs at 40% confluency were
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used for sodding. During the sodding period, HUVEC and HUASMC media was used to deactivate the
trypsin again. The speed was increased by 15 RPM every two hours. The speed was left at 60 RPM
overnight and the next day was increased until 90 RPM was reached. The next day, a check up of the
system took place. The CO2 level was low and the tank was replaced. The one BVM system was taken
down and image analysis was performed using the fluorescence microscope and the SEM.
Setup 8

The setup design was to implement three current BVM systems and one new BVM system. The only
difference between the two BVM systems was the bioreactor reservoir designs; the new design is
illustrated in Figure 9. Four 3 cm long 3 mm in diameter scaffolds were cut off the mandrels and left in
the desiccator in preparation for the setup. The setup was delayed because there were complications
with the sterilization process. Although three of the lab’s BVM system undergone EtO sterilization, the
new bioreactor had not undergone sterilization; however, the design was thoroughly cleaned with IPA
and dried before using the design. The new design was created by a previous Tissue Engineering
student for a class project. Since there had been complications with leakage and tubing tears, a new
design was used as a comparison for function. The setup was performed using the dual sod protocol
for 24 hours because the setup was not completely sterile. After the conditioning procedure, the three
current systems were clamped onto a pump. The new bioreactor system was clamped onto an eightroller pump a shelf below the other systems. Once transmural flow was introduced, bubbles formed in
the new bioreactor chamber. So many bubbles formed that the bioreactor chamber’s top began to
come off the system. The new bioreactor design was taken down. Additionally, one of the normal BVM
systems had to be taken down because the tubing tore in the pump. Therefore, there were only two
systems that were seeded with cells. After the transmural flow and rest period, luminal flow was
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introduced at 15 RPM. The RPM was increased every hour and half until 60 RPM was reached; 60 RPM
was left overnight. The next morning the RPM was increased until it reached 90 RPM. The speed was
left at 90 RPM for three hours before the system was taken down. Image analysis was performed using
the fluorescence microscope and the SEM.

Figure 9: Bioreactor used in Setup 7 for comparison study

Setup 9
Prior to the setup, it was looked into creating a sleeve for the tubing so it would not tear or kink while
mounted onto the pump. A mock BVM system was created using water to observe if the sleeve
prevented kinking of the tubing in the pump. However, the water experiment proved to only worsen
the kinking. Therefore, another one-day BVM setup was executed to see if it was possible to get at
least three BVMs to analyze. The setup consisted of four systems and PLGA scaffold that were 3 cm
long and 4 mm in diameter. During scaffold placement, the scaffold in the fourth BVM system stayed
extremely kinked. On the sodding day morning, it was observed that media in two of the systems were
bright yellow. The other two systems’ media turned orange. The setup was taken down due to color
change of the media.
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Take Down, Fixation, and Analysis
The BVM systems were removed from the humidified incubators at predetermined time points. The
scaffold was cut out of the system and carefully placed in a 15mL conical filled with histochoice.
Bisbenzidmide staining (BBI, diluted Milli-Q water) was performed on the scaffolds and viewed using
the fluorescence microscope. The scaffolds were cut in half longitudely to divide the bottom and top of
the scaffold. After imaging with the fluorescence microscope the scaffold were immediately removed
from the BBI stain and placed back in the conicals filled with histochoice. In order to perform SEM
imaging, the scaffolds were dehydrated in a series of EtOH concentrations and placed in the desiccater
until all the moisture was gone. Imaging with the SEM was then performed. See Appendix B for
complete protocol.
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Section 3. Results
Setup 1
Observations
The setup consisted of one BVM system and the setup was intended for a 24 hour setup with single
sod of fibroblast cells on to a 3 cm long EPTFE scaffold. The purpose of this experiment was to learn the
BVM protocol with the aid of Dr. Cardinal. Even though the setup was a non sterile setup, the sterile
technique was learned. The sterile technique was broken because of the lack of experience; there were
no contaminations or complications with the setup. Image analysis was performed to learn how to use
the fluorescence microscope as well as the BBI protocol.
Data/Results
None
Setup 2
Observation
The setup included only a single sod of HUVECs for 24 hour incubation using one BVM. This was the
first setup using HUVECs on EPTFE. During conditioning, there was difficulty in priming the ports;
inverting the reservoir did not allow the media to travel throughout the tubing. Conditioning was only
performed for ten minutes. Techniques that were strictly applicable to 3T3s were transferred over to
HUVECs. For example, the ratio of deactivation media to trypsin was suppose to be 2:1 HUVEC media
to trypsin and 1:1 ratio was actually implemented. The sterile technique was still not completely
mastered yet, an example of this lack of mastery was when hands crossed over the bioreactor
chambers with aseptic gloves. During the conditioning period, bubbles started forming directly over
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the scaffold; the bubbles subsided and eventually disappeared. Leaking occurred at the reservoir
outlets; Parafilm was wrapped around the outlets and leaking ceased. The setup was taken down the
next day, and the scaffold was removed from the fittings and placed in histochoice. The main
challenges faced in Setup 2 were: leaking, kinked scaffolds, and the inexperience of the BVM protocol.
Data/Results
None
Setup 3
The confidence in the technique was not mastered yet; therefore one more practice setup was
conducted. The purpose of the setup was to master the single sod protocol using sterile technique. The
setup was another 24 hour setup using 3T3s and EPTFE as the scaffold material. During the
conditioning aspect of the experiment, small leaking occurred at the reservoir outlets; the leaking was
stopped by using Parafilm around the outlets. The setup was taken down the next day. The challenges
of Setup 3 were leaking and the inexperience of the BVM setup.
Data/Results
None
Setup 4
The setup was designed with two one-day BVMs and two three-day BVMs. The PLGA scaffolds were 4
cm in diameter and 3 cm in length. The goal of this experiment was to learn and perform the dual sod
protocol using PLGA. The purpose of having two different time periods was to compare the cell
confluency on the lumen lining of the scaffold. The prior experiments were only single Sod of HUVECs
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and using ePTFE. The setup involved a lot of new introductions for the student. The student never
performed a dual sod setup up or multiple BVM systems at one time. PLGA was also used for the first
time by the student. One of the scaffolds was placed in IPA instead of 70% EtOH. The scaffold was
flushed with PBS and was placed in the bioreactor that was a one-day setup. The experiment was
conducted in sync with the previous written protocol. On the same day as the pressure sodding, one of
the three-day BVM’s tubing tore in the pump and it was immediately taken down. However, the
leaking did not cease, so the one-day BVM system was taken down. The day following the sodding, the
one-day setups were taken down and one of them was used for RNA isolation; the other one-day BVM
was placed in fixative right away. The scaffolds were labeled according to the order the cells were
sodded. During the imaging of Vessel 1, it could not distinguish the mark that was made to
differentiate the top from the bottom of the scaffold; therefore, scaffold one’s two halves are referred
to as side one and two rather than bottom versus top. BBI nuclear stain of vessel 1 is shown in Figures
10 and 11. Figures 12 and 13 illustrate the vessel 2’s cell deposition. Some of the challenges faced were
the lack of experience with the dual sod protocol, multiple systems, and the new polymer. Leaks and
tube tearing were two issues experienced during the setup. Leaking and tubing tearing are two other
issues that were experienced in the setup.
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Data/Results

Figure 10: 10x BBI stain of PLGA with HUVECs and HUVSMCs: middle location of side 1 of vessel 1.

Figure 11: 10x BBI stain of PLGA with Dual Sod: middle location of side 2 of side 1

Figure 12: 10x BBI stain of PLGA with Dual Sod: proximal side of the top of Vessel 2
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Figure 13: 10x BBI Stain of PLGA with Dual Sod: Vessel 2’s proximal side of the bottom

Setup 5
The setup design was similar to the fourth setup because there were two one-day setups and two
three-day setups. The purpose of the experiment was to master the protocol in order to eliminate
trivial errors and have four BVMs to analyze. The analysis would include SEM imaging along with
fluorescence imaging. During the conditioning procedure, priming one of the one-day did not occur.
When the reservoir was inverted, the media did not travel to the rest of the system. It was difficult to
discern what caused the system not to be a closed system, so the system was not conditioned
properly. Additionally as mentioned in the methods, one of the scaffolds stayed kinked after being
fixed in place. When the BVM was placed in the incubator, accumulation of bubbles occurred and there
was no flow. There is difficulty with the placement of the PLGA scaffolds. The scaffold must be slightly
bent in a semi circle shape in order to have it properly placed in the fixtures. Since PLGA is not a
compliant material, sometimes the material remains kinked after slight bending. The setup was left
with two three-day setups and one one-day setup. The analysis required two different times of BBI
staining. During the first imaging session using the fluorescence, the microscope did not properly.
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Immediately, the cells were placed back in histochoice and a week later were placed in a BBI dilution
and reimaged. Below are the figures from both rounds of imaging. There was a malfunction with the
fluorescence, so the BBI imaging was performed twice. After the first attempt, the samples were
removed from the BBI dilution and placed back into the conical of histochoice. A week later, the
scaffolds were placed in a new BBI dilution and imaged. Challenges faced during the BVM were leaking
in the system and design issues with the fittings.

Figures 14-16 illustrate the poor quality of imaging performed during the first attempt. Figure 17 and
Figure 18 depict the minimal cell coverage observed during the second round of imaging.

Figure 14: 4X BBI stain of PLGA with dual sod: one-day setup of vessel one’s bottom distal side
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Figure 15: BBI stain of PLGA with dual sod: one-day setup of vessel one’s bottom middle side

Figure 16: BBI stain of PLGA with dual sod: three-day setup of vessel three’s bottom middle side

Figure 17: 4X BBI stain of PLGA with dual sod: one-day setup of vessel one’s side two middle side
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Figure 18: 4X BBI stain of PLGA with dual sod: three-day setup of vessel 3 top middle side
Setup 6
The setup involved a three day setup with four BVM systems. The purpose of the experiment is to dual
sod HUVECs and HUVSMCs onto PLGA scaffolds and perform a four day in vitro BVM set up to observe
similar confluent cell linings among each of the vessels. Since there were so many delays, time was
scarce. The cells were expanded at a very slow rate because the cell passages were P1s compared to
the usually P4s used for the experiment. Since time was a constraint and there was a lack of cells, three
systems were conditioned instead of four. Flow did not occur through two of the systems the next
morning, two systems’ tubing were cleaved from the pump overnight. One vessel was sodded with
both one T225 flask of HUASMCs and HUVECs according to protocol, and the setup duration was 48
hours. Time was definitely the biggest challenged faced during the completion of Setup 6. The setup
was originally thought to take two and a half weeks, but took roughly seven weeks to complete. The
EtOH sterilization process had a malfunction similar to Setup 5. The loss and replacement of HUVECs
and HUASMCs caused a huge delay as well. During the setup, it was noticed the tubing was kinked in
the eight-roller pump and the flow was inhibited. Repetitive problems were: tube tearing and kinks in
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the pump. Figures 19 and 20 illustrate the small amount of cell of disposition on the distal side. It was
expected to have a greater confluency than what appears. The cells are sparse on the polymer fibers as
shown in Figures 21-22.

Figure 19: 4X BBI stain of PLGA with dual sod: two-day setup of vessel 3 bottom distal side

Figure 20: 4X BBI stain of PLGA with dual sod: two-day setup of vessel three’s top distal side
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Figure 21: SEM image of vessel three’s distal bottom side

Figure 22: SEM image of vessel three’s top distal side
Setup 7
The setup originally a three day setup intended to use four BVM systems. The purpose of the setup
was similar to setup 6 in that it was to dual sod HUVECs and HUASMCs onto PLGA scaffolds and
perform a four day in vitro BVM set up to observe similar confluent cell linings among each of the
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vessels. The length of the setup was longer than expected. The expanding of cells took a long time. The
freezing down of the cells and thawing within a week also added a lot of time. Leaking and tube tearing
continued to be issues. Quantative analysis still could not be performed because there needs to be at
least three for the setup to be statistically significant. Only one vessel was imaged and Figures 23-25
illustrate the lack of cells attached to the luminal wall of the scaffold. Figures 26-27 are the SEM
images acquired from the single vessel. The cell attachment is very hard to observe by the SEM images.

Figure 23: 10x BBI Image of the bottom distal side of Vessel

Figure 24: 10x BBI image of the bottom middle side of vessel
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Figure 25: 10x BBI Image of the top middle side of Vessel

Figure 26: SEM image of the bottom middle side of vessel
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Figure 27: SEM image of the top proximal side of vessel

Setup 8
The prior two setups resulted in leakage and tubing tears, so this 24 hour setup was designed to use
three of the lab’s bioreactors and implement a student’s new design for comparison (Figure 9). The air
bubbles could not be removed during conditioning. Once the systems were clamped to the pump, the
bioreactor media in the new design continued to form into bubbles and the cap was elevated from its
original position by the pressure. When the new design was dissembled, it was found that the top is
very difficult to maneuver on and off and this poses a problem if there were cells on the scaffold as
they may become dislodged if the bioreactor was used for the sodding process. The setup was left
with the three original bioreactors after conditioning was complete. The next morning when the cells
were suppose to be sodded, one of the bioreactor’s tubing was cleaved while in the pump and leaked
everywhere. The tubing has cleaved multiple times while mounted on the pump; I tried after the setup
to create a sleeve for the tubing so it has a thick protective barrier. However, this caused the tubing to
become more kinked. Therefore, only two BVM systems were left and two scaffolds were sodded with
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HUASMCs first and then HUVECs. The analysis was performed using BBI under the fluorescence
microscope and the SEM. The fluorescence imaging revealed cells on the bottom and top of the
scaffold at the proximal, middle, and distal locations; however, the cell yield did not match what was
expected. Figures 28-29 illustrate the bottom middle of both vessel one and vessel two. Figures 30-31
illustrate bottom proximal of both the vessels. The figures illustrate that the there is not a consistent
lining among the blood vessels. Figures 32-33 are the SEM images acquired from vessel two. Like
previous setups, the SEM images reveal the lack of cell adhesion to the PLGA fibers.

Figure 28: 10x BBI image of Vessel one’s bottom middle side

Figure 29: 10x BBI image of vessel two’s bottom middle side
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Figure 30: 10x BBI image of vessel one’s bottom proximal side

Figure 31: 10x BBI image of vessel two’s bottom proximal side
V2 proximal

Figure 32: SEM image of Vessel two’s bottom middle side
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Figure 33: SEM image of vessel two’s top middle side
Setup 9
The setup was designed to be a 24 hour setup with non EtO sterilized BVM systems. The purpose of the
setup was to investigate the different aspects of the setup that was challenging and what parts went
wrong; ideally though, I would be able to analyze all four scaffolds. The scaffolds needed to be kinked
in order to be locked into the fittings. Usually the kink is so minuscule that it does not affect the
scaffold’s shape; however, the fourth scaffold I placed became permanently kinked. I continued the
assembly and marked the bioreactor. The next morning I opened the incubator, and two of the four
bioreactor’s media turned bright yellow from the media’s normal pink-red color as seen in Figure 34.
One of the bioreactors looked bright orange-yellow and the fourth bioreactor was an abnormal color
as well, but not quite yellow. All four systems were taken down, therefore the sodding of the cells were
not performed.
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Figure 34: Image of Setup 9 illustrating the change in media color

Section 4. Discussion
Originally the aim of the senior project was to reproduce the consistent cell linings amongst the BVM
systems using an established BVM protocol. Challenges faced during the early setups prevented
analysis of n=3; therefore no quantitative analysis was performed. As a result, the aim of the senior
project was reestablished to investigating the ability to create the reproducible BVMs.
One of the biggest challenges tackled during the BVM setups was time. The BVM protocol is
meant to take about two weeks to complete. Setup durations usually took longer than expected.
Delays resulted from a multitude of reasons. The vendors that provided the supplies took a while to
ship the order or were difficult to get into contact with about ordering supplies. The veterinary clinic
on Cal Poly’s campus executed the EtO sterilization and often caused delays for the BVM system.
During the senior project experimentation, the clinic underwent a new management. Therefore, there
was a learning curve with the sterilization process. When the machine experienced a malfunction, it
took longer to get the machine working properly again than it previously had. The clinic’s summer
hours are dramatically reduced, so it was hard to get into contact with the work staff about
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sterilization. Since the protocol was under construction and was altered a few times, the time it took
to feel confident with the procedure caused delays in the setup.
The current BVM caused challenges that impeded a full setup to be attained. The current
bioreactor design was suppose to be a temporary design. The Tupperware was worn down from the
constant use and the sterilization process. Cracks formed in the bottom corners of the bioreactor. The
leaks in the bioreactor were hard to fix with parafilm, so the leaks caused the system to be taken down
during the time of setup. Leaks occurred at the o-ring locations where the tubing was attached to the
bioreactor. Parafilm was implemented to stop the linking and it had worked only a few times. Leaking
also happened at the o-ring locations on the reservoir top. Again, parafilm only worked occasionally to
stop the leaking. Often times, the tubing would kink when it was clamped to the eight-roller pump.
The kink would impede flow from the rest of the system. The kinking resulted in tubing tears. A sleeve
was attempted to be used so the current material would not kink, however, it just worsened the
problem. Lastly, the fittings where the scaffolds were attached did not allow for much leeway. The
scaffolds were slightly bent in order to be placed in the fittings. Since PLGA is not a compliant material,
it would sometimes stay kink. The kinking of the scaffold caused bubbles to form and had to be taken
down most times.
The immediate work following the work of the senior project would be to come up with
constraints for a more robust design. The bioreactor has to be made out of a more durable material.
The design should include more flexible fittings that attach to the scaffold. If the fittings are more
flexible, there would not be a need to kink the scaffold for placement. Different tubing for the system
should also be investigated for a more durable material. The tubing used currently and also gets kinked
in the eight roller pump. Completing another comparison study with a different design than is currently
used would also be good to determine what the best design for the tissue engineering lab is.
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Appendix A: BVM Protocols
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Appendix B : Imaging Protocols
Procedure for Bisbenzimide (BBI) Evaluation of Cell-Sodded Scaffolds
Written by: R. Dalton Chavez

1. Wrap nonsterile 15-mL conicals in foil. Thoroughly label conicals for all samples.
2. Make BBI solution. Always keep stock solution wrapped in foil!
a. Use small tube of stock solution and dilute 1:1000 with milli-Q water (10 L stock solution in 10 mL
water). Use pipette aid from room 209 hood for milli-Q water; spray pipette aid before placing back
in hood.
b. Mix by inverting.
3. Put on safety glasses. Cut samples with blade or scissors, being careful to not disrupt cell lining inside lumen
(squeezing, touching, and scraping can all disrupt lining and ruin experiment).
4. Use washed forceps to place samples in corresponding 15-mL conicals that contain BBI solution. Carefully
keep track of samples. Leave foil on conicals.
a. Let samples soak for at least 15 minutes (longer is better).
5. Put away extra stock solution. Clean up preparation area.
6. With permission or help from Dr. Cardinal, use fluorescent microscope to obtain en face images. Take forceps
to use at microscope. See figure 1 for pictures of steps below.
a.
b.
c.
d.
e.
f.
g.
h.
i.
j.
k.
l.
m.
n.
o.
p.
q.
r.
s.
t.

Log into notebook (fluorescence; initials; date; time and lamp hours).
Turn turret to setting 4.
Turn on Olympus lamp (green switch).
Turn on Optiscan wheels (black switch).
Turn on camera (black switch).
Set filter wheel 1 to 1, and set filter wheel 2 to 1.
Open shutter:
Set Prior keypad to shutter S1.
Dial objectives to desired magnification (typically 4x and 10x for BBI images).
Set thin bar to icon of eye and camera.
Sign into computer by clicking Kristen’s account (password can be obtained from Kristen).
Click QCapture Pro (on desktop).
Click camera icon at top of QCapture Pro window:
Place slide on microscope. Place sample on slide.
See figure 2.
Manually adjust microscope to clarify image.
If scaffold is too wet, carefully blot end of scaffold on Kim wipe.
Take pictures. Save pictures if desired (labeled with sample info, initials, and magnification).
Quit QCapture Pro. Log out of computer.
Shut down microscope by switching off Olympus lamp, switching off Optiscan wheels, switching off
camera (on top of microscope), closing shutter, and setting thin bar to icon of eye.
u. Log out of notebook.
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Figure 1: Microscope anatomy. Letters
correspond to step 6 in protocol.
a. Click “More”.

b. Click “Preview”.
c. Click setting 1.

d. Click “Auto Set”. If
“White Balance” window
pops up, close it.
e. Type larger number
in mmm blank for
lighter image and
smaller number for
darker image.
f. Click + to increase size
of image window and
– to decrease size of
image window.

Figure 2: QCapture Pro control panel.
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Sample Preparation for Scanning Electron Microscopy
Materials:
6 Coverslips with cells on them
Distilled water Histochoice
100% Ethanol 50 mL conical
tubes for waste
Note: for all steps, do not pipette any solutions directly on to the cells as this will dislodge
cells.
1. Remove cell media from each well.
2. Remove the growth media and replace with 3 mL of fixative (Histochoice) for each well of a six well plate.
Cover each coverslip with 3 mL of solution for 30 minutes at room temperature. Cover six well plate with
lid.
3. Remove histochoice and put into 50 mL conical tube as liquid waste. Clearly label your waste
containers.
4. Gently wash the cells with distilled water. Repeat 4 times.
5. Prepare the following solutions by diluting with distilled water: 25% ethanol, 50% ethanol, 70%
ethanol, 90% ethanol, and 100% ethanol. You will be using 1 mL of solution per coverslip.
6. Dehydrate the cells in the following steps:
25% ethanol for 5 minutes
50% ethanol for 5 minutes
70% ethanol for 5 minutes
95% ethanol for 5 minutes
100% ethanol for 5 minutes (2 times)
Due to the fragility of the coverslips, you will be performing the dehydration steps within the 6 well
plate. Completely remove the solution from the previous step.
7. Remove coverslips from solution and air dry. Mount each coverslip on a separate glass slide
using double stick tape. Ensure the coverslips are oriented with the cells exposed to air. Transfer
slides to petri dishes for transport to SEM microscope. Make sure coverslips are completely dry
before imaging.
8. You are now ready to image your cells.
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